+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

  • ID: 5017480
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 81 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Nepsone ehf
  • Pharmnovo AB
  • MORE
Calcitonin Gene Related Peptide - Pipeline Review, H1 2020

Summary

Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 10 molecules. The latest report Calcitonin Gene Related Peptide - Pipeline Review, H1 2020, outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception. The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Furthermore, this report also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Nepsone ehf
  • Pharmnovo AB
  • MORE
  • Introduction
  • Report Coverage
  • Calcitonin Gene Related Peptide (CGRP) - Overview
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Living Cell Technologies Ltd
  • Nepsone ehf
  • Pharmnovo AB
  • Serometrix LLC
  • Teva Pharmaceutical Industries Ltd
  • United Neuroscience Ltd
  • Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
  • AFAP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eptinezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fremanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Calcitonin Gene Related Peptide (CGRP) - Dormant Products
  • Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
  • Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by AfaSci Inc, H1 2020
  • Pipeline by Aptarion biotech AG, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by H. Lundbeck AS, H1 2020
  • Pipeline by Living Cell Technologies Ltd, H1 2020
  • Pipeline by Nepsone ehf, H1 2020
  • Pipeline by Pharmnovo AB, H1 2020
  • Pipeline by Serometrix LLC, H1 2020
  • Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
  • Pipeline by United Neuroscience Ltd, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Living Cell Technologies Ltd
  • Nepsone ehf
  • Pharmnovo AB
  • Serometrix LLC
  • Teva Pharmaceutical Industries Ltd
  • United Neuroscience Ltd
Note: Product cover images may vary from those shown
Adroll
adroll